Hydroxyurea is a cytotoxic agent widely used in the treatment of myeloproliferative disorders. It is considered a-well-tolerated antineoplastic drug, with a dose-related bone marrow suppression as main adverse effect. This report describes a patient with essential thrombocythemia who developed an interstitial pneumonitis and respiratory failure within 4 years from beginning therapy with hydroxyurea (HU). After discontinuing of HU. both clinical and radiological resolution of pneumonitis occurred. In conclusion, HU-induced pulmonary toxicity is a potentially life-threatening side effect.
Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature / Internullo, M., Giannelli, V., Sardo, L., Antonaglia, C., Villani, T., Angelici, E., Palange, P.. - In: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES. - ISSN 2284-0729. - 18:2(2014), p. 190-3.
Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature
INTERNULLO, MATTIA;GIANNELLI, VALERIO;SARDO, LIBORIO;ANTONAGLIA, CATERINA;VILLANI, TULLIA;ANGELICI, Elena;PALANGE, Paolo
2014
Abstract
Hydroxyurea is a cytotoxic agent widely used in the treatment of myeloproliferative disorders. It is considered a-well-tolerated antineoplastic drug, with a dose-related bone marrow suppression as main adverse effect. This report describes a patient with essential thrombocythemia who developed an interstitial pneumonitis and respiratory failure within 4 years from beginning therapy with hydroxyurea (HU). After discontinuing of HU. both clinical and radiological resolution of pneumonitis occurred. In conclusion, HU-induced pulmonary toxicity is a potentially life-threatening side effect.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
